Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14497MR)

This product GTTS-WQ14497MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14497MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ314MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ12608MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ13406MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ10629MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ9770MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ12661MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ11139MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ6762MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW